

What Urologists Want To Know: Addressing Current Questions and Controversies in the Management of Prostate Cancer

*A Virtual CME Satellite Symposium During the
American Urological Association (AUA) 2021 Annual Meeting*

Monday, September 13, 2021

5:00 PM – 6:30 PM ET

Faculty

Leonard G Gomella, MD

Maha Hussain, MD, FACP, FASCO

A Oliver Sartor, MD

Neal D Shore, MD

Moderator

Neil Love, MD

Faculty



Leonard G Gomella, MD

The Bernard W Godwin Professor of Prostate Cancer
Chairman, Department of Urology
Senior Director, Clinical Affairs, Sidney Kimmel Cancer Center
Enterprise VP for Urology, Jefferson Health System
Thomas Jefferson University and Hospital
Philadelphia, Pennsylvania



Neal D Shore, MD

Director, CPI, Carolina Urologic Research Center
Chief Medical Officer, Surgery/Urology
GenesisCare, US
Medical Director, CUSP: Clinical Research
Consortium
Myrtle Beach, South Carolina



Maha Hussain, MD, FACP, FASCO

Genevieve Teuton Professor of Medicine
Division of Hematology/Oncology
Deputy Director
Robert H Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Chicago, Illinois



Moderator

Neil Love, MD

Research To Practice
Miami, Florida



A Oliver Sartor, MD

Laborde Professor for Cancer Research
Medical Director, Tulane Cancer Center
Assistant Dean for Oncology
Tulane Medical School
New Orleans, Louisiana

Commercial Support

This activity is supported by educational grants from Merck and Sanofi Genzyme.

Dr Love — Disclosures

Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers

Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Dr Gomella — Disclosures

Advisory Committee	AstraZeneca Pharmaceuticals LP
---------------------------	--------------------------------

Dr Hussain — Disclosures

Advisory Committee and Consulting Agreements	AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Pfizer Inc
Honoraria	Astellas, AstraZeneca Pharmaceuticals LP, Phillips Gilmore Oncology Communications Inc, Precisca, Sanofi Genzyme, UroToday
Patents, Royalties, Other Intellectual Property	Systems and Methods for Tissue Imaging, 3676, Licensed to IMBIO


Dr Sartor — Disclosures

Consulting Agreements	Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bavarian Nordic, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Bristol-Myers Squibb Company, Clarity Pharmaceuticals, Clovis Oncology, Constellation Pharmaceuticals, Dendreon Pharmaceuticals Inc, EMD Serono Inc, Fusion Pharmaceuticals, ITM Isotopen Technologien München AG, Janssen Biotech Inc, Merck, Myovant Sciences, Myriad Genetic Laboratories Inc, Noria Therapeutics Inc, Novartis, Noxopharm, Pfizer Inc, Point Biopharma Inc, Progenics Pharmaceuticals Inc, Sanofi Genzyme, Telix Pharmaceuticals, TeneoBio, Theragnostics
Contracted Research	Advanced Accelerator Applications, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Constellation Pharmaceuticals, Endocyte Inc, Invitae, Janssen Biotech Inc, Lantheus, Merck, Progenics Pharmaceuticals Inc, TeneoBio
Data and Safety Monitoring Board/Committee	AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Pfizer Inc, Myovant Sciences

Dr Shore — Disclosures

Consulting Agreements	AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boston Scientific Corporation, Bristol-Myers Squibb Company, CG Oncology, Clovis Oncology, Dendreon Pharmaceuticals Inc, Exact Imaging, Exact Sciences Inc, FerGene, Foundation Medicine, GenesisCare, Invitae, Janssen Biotech Inc, MDxHealth, Merck, Myovant Sciences, Myriad Genetic Laboratories Inc, NymoxPharmaceutical Corporation, Pacific Edge, Pfizer Inc, Phosphorus, Propella Therapeutics Inc, Sanofi Genzyme, Sesen Bio, Tolmar, UroGen Pharma
Speakers Bureau	Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Foundation Medicine, Guardant Health, Janssen Biotech Inc, Merck, Pfizer Inc

We Encourage Clinicians in Practice to Submit Questions



Feel free to submit questions now before the program begins and throughout the program.

Familiarizing Yourself with the Zoom Interface

Expand chat submission box

The screenshot shows a Zoom meeting interface. At the top, there are video thumbnails for participants: RTP Coordinat..., Kirsten Miller, RTP Mike Rivera, and Lisa Suarez. A 'Recording...' indicator is visible on the left. The main content is a slide titled 'Meet The Professor Program Steering Committee' featuring six members:


- John N Allan, MD**: Assistant Professor of Medicine, Weill Cornell Medicine, New York, New York
- Ian W Flinn, MD, PhD**: Director of Lymphoma Research Program, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, Tennessee
- Steven Coutre, MD**: Professor of Medicine (Hematology), Stanford University School of Medicine, Stanford, California
- Prof John G Gribben, MD, DSc, FMedSci**: Chair of Medical Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, United Kingdom
- Matthew S Davids, MD, MMSc**: Associate Professor of Medicine, Harvard Medical School, Director of Clinical Research, Division of Lymphoma, Dana-Farber Cancer Institute, Boston, Massachusetts
- Brian T Hill, MD, PhD**: Director, Lymphoid Malignancy Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio

The chat window on the right is expanded, showing two messages from 'Me to Panelists' and 'Me to Panelists and Attendees' at 4:31 PM and 4:32 PM respectively. Each message contains a welcome message and a link to a PDF slide: http://images.researchtopractice.com/2021/Meetings/Slides/MTP_ToGo_CLL_2021_April1.pdf. A red arrow points to the white line above the 'Type message here...' input box, indicating how to expand the chat area.

Drag the white line above the submission box up to create more space for your message.

Familiarizing Yourself with the Zoom Interface

Increase chat font size



The screenshot displays a Zoom meeting interface. At the top, there are video thumbnails for participants: RTP Coordinator, Kirsten Miller, RTP Mike Rivera, and Lisa Suarez. The main content area shows a slide titled "Research To Practice CME Planning Committee Members, Staff and Reviewers" with the text: "Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose." On the right, the chat window is open, showing a message from "Me to Panelists" at 4:32 PM. A red arrow points to the font size adjustment icon (a square with a plus sign) in the chat window's header. The chat message contains a welcome message and a link to a PDF document: http://images.researchtopractice.com/2021/Meetings/Slides/MTP_ToGo_CLL_2021_April_1.pdf. The chat window also shows a "150%" font size indicator and a "Type message here..." input field.

**Press Command (for Mac) or Control (for PC) and the + symbol.
You may do this as many times as you need for readability.**


ONCOLOGY TODAY

WITH DR NEIL LOVE

Key Presentations on Genitourinary Cancers from the 2021 ASCO Annual Meeting



DR ARJUN BALAR
NYU PERLMUTTER CANCER CENTER



Meet The Professor

Optimizing the Selection and Sequencing of Therapy for Patients with Renal Cell Carcinoma

Tuesday, September 14, 2021

5:00 PM – 6:00 PM ET

Faculty

Neeraj Agarwal, MD

Moderator

Neil Love, MD

Meet The Professor

Optimizing the Clinical Management of Hodgkin and Non-Hodgkin Lymphomas

**Thursday, September 16, 2021
5:00 PM – 6:00 PM ET**

Faculty

Loretta J Nastoupil, MD

Moderator

Neil Love, MD

Meet The Professor

Optimizing the Selection and Sequencing of Therapy for Patients with Advanced Gastrointestinal Cancers

Friday, September 17, 2021
12:00 PM – 1:00 PM ET

Faculty

Philip A Philip, MD, PhD, FRCP

Moderator

Neil Love, MD

Meet The Professor

Optimizing the Selection and Sequencing of Therapy for Patients with HER2-Positive Breast Cancer

Wednesday, September 22, 2021
5:00 PM – 6:00 PM ET

Faculty

Sara M Tolaney, MD, MPH

Moderator

Neil Love, MD

Meet The Professor

Optimizing the Selection and Sequencing of Therapy for Patients with Advanced Gastrointestinal Cancers

Monday, September 27, 2021
5:00 PM – 6:00 PM ET

Faculty

Zev Wainberg, MD, MSc

Moderator

Neil Love, MD

Meet The Professor

Optimizing the Selection and Sequencing of Therapy for Patients with Triple-Negative Breast Cancer

Tuesday, September 28, 2021
5:00 PM – 6:00 PM ET

Faculty

Professor Peter Schmid, MD, PhD

Moderator

Neil Love, MD

Thank you for joining us!

CME credit information will be emailed to each participant within 3 business days.



MARRIOTT MARQUIS
SAN FRANCISCO

... syndrome) and multiple recurrent
...
... bilateral pelvic lymph
... (0/7) Stage IIIb prostate
...
... Not a candidate for RT, hence
... led on enzalutamide, continuing
...
... whether to add in another hormone in
... to balance doubling time, time since

Case 2: 57-year-old

- History of P10CH-1 deficiency (Guthrie, Marfan syndrome) and multiple recurrent basal cell cancers; currently on hedgehog inhibitor vismodegib; MPO, asymptomatic myeloma
- 2010: PSA 15, core needle biopsy, radical prostatectomy/bilateral pelvic lymph node dissection in Gleason 4+3=7 pT2a/b (0/7) Stage IIIb prostate adenocarcinoma
- Postop PSA rose within 8 months of surgery. Not a candidate for RT, hence treated with GnRH. Failure 1 year later; started on enzalutamide, continuing GnRH. Current PSA undetectable.

Questions for the faculty:
In a more typical situation, how do you decide whether to add in another hormone in a patient on ADT with a rising PSA? How do you balance doubling time, time since original surgery, time on ADT and PSA level?
How do you choose which androgen?























MARRIOTT MARQUIS
SAN FRANCISCO

5:59





About

MARRIOTT MARQUIS
SAN FRANCISCO

ASUS













A 65-year-old man s/p radical prostatectomy followed by PSA-only recurrence (M0) receives an LHRH agonist. His PSA level is 14 ng/dL with a doubling time of 3 months. His imaging are negative. The patient has asked you to respond. How would you respond?

- Less than 5%
- 5%-10%
- 11%-25%
- 26%-50%
- 51%-70%
- Greater than 70%





A 10-year-old male with medical comorbidities followed by cardiac arrest for 10 minutes. Resuscitation was initiated and he was transported to the PICU. A PICU resident, Dr. J. Smith, MD, and a PICU fellow, Dr. A. Jones, MD, were present. The patient was intubated and placed on mechanical ventilation. The patient was transferred to the PICU and remained stable for 24 hours. How do you respond?

Response	Percentage
1. Continue on current management	45%
2. Discontinue mechanical ventilation	35%
3. Transfer to the ICU	15%
4. Discontinue life support	5%

















...S
...ND, MD

...ARTOR, MD

...SCHER, MD

...D SMITH, MD, PhD

...ENBERG, MD

Yes (biochemical recurrence with rapid PSA doubling time)

Yes (M0 disease)

Yes (no significant metastatic disease or high-grade rapid recurrence)

Yes (PSA-only disease with absence of nodal metastases)

Yes (PSA nadir > 2 ng/mL multiple times)

















